Trust Department MB Financial Bank N A Sells 3,495 Shares of Johnson & Johnson (JNJ)

Trust Department MB Financial Bank N A trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 95,443 shares of the company’s stock after selling 3,495 shares during the period. Johnson & Johnson makes up 1.5% of Trust Department MB Financial Bank N A’s portfolio, making the stock its 14th biggest holding. Trust Department MB Financial Bank N A’s holdings in Johnson & Johnson were worth $12,317,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Fundsmith Equity Fund L.P. bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $552,762,000. Peoples Financial Services CORP. lifted its stake in Johnson & Johnson by 20.4% during the third quarter. Peoples Financial Services CORP. now owns 30,668 shares of the company’s stock worth $4,237,000 after purchasing an additional 5,190 shares during the period. Sather Financial Group Inc lifted its stake in Johnson & Johnson by 3.7% during the second quarter. Sather Financial Group Inc now owns 11,051 shares of the company’s stock worth $1,341,000 after purchasing an additional 399 shares during the period. QUANTRES ASSET MANAGEMENT Ltd bought a new position in Johnson & Johnson during the third quarter worth about $829,000. Finally, Foundation Resource Management Inc. bought a new position in Johnson & Johnson during the third quarter worth about $208,000. Institutional investors own 67.29% of the company’s stock.

A number of research analysts have commented on JNJ shares. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Citigroup dropped their price objective on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a report on Wednesday, January 2nd. Wells Fargo & Co reaffirmed an “outperform” rating and set a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Barclays reaffirmed an “equal weight” rating and set a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Finally, Morgan Stanley set a $140.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Thursday, December 20th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $143.58.

JNJ stock traded up $0.54 during midday trading on Monday, reaching $136.52. The company’s stock had a trading volume of 4,661,976 shares, compared to its average volume of 6,780,161. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99. The stock has a market cap of $362.76 billion, a PE ratio of 16.69, a PEG ratio of 2.07 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.20 and a current ratio of 1.47.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 22nd. The company reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.02. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The firm had revenue of $20.39 billion for the quarter, compared to analysts’ expectations of $20.27 billion. During the same period last year, the firm earned $1.74 earnings per share. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. As a group, sell-side analysts predict that Johnson & Johnson will post 8.58 earnings per share for the current fiscal year.

Johnson & Johnson declared that its Board of Directors has initiated a share repurchase plan on Monday, December 17th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 1.5% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

COPYRIGHT VIOLATION NOTICE: “Trust Department MB Financial Bank N A Sells 3,495 Shares of Johnson & Johnson (JNJ)” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/trust-department-mb-financial-bank-n-a-has-12-32-million-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Intrinsic Value and Stock Selection

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.